Indications

Prescribing Information

Next Page Icon

Medication Guide

Next Page Icon
Potential OPDIVO® (nivolumab) user playing guitar to her partner in a field.
Potential OPDIVO® (nivolumab) user playing guitar to her partner in a field.

Clinical trial results for
previously treated 

advanced bladder or
urinary tract cancer

For certain adults with previously treated advanced
bladder cancer (urothelial carcinoma)

Actor portrayals.

An FDA-approved immunotherapy that may help tumors either shrink or disappear completely

About the clinical trial

In a clinical trial, the overall response rate to OPDIVO was looked at in 270 people with advanced bladder cancer that was previously treated with treatments that did not work or stopped working. Nearly a third of people had already been treated with multiple therapies for advanced bladder cancer, and their ages ranged from 38 to 90 years old.

Some people saw their tumors shrink or disappear completely with
OPDIVO at 6 months

OPDIVO

Tumors disappeared completely (complete response)

7 out of 270 people, or 3%, saw tumors disappear completely in response to OPDIVO® for previously treated advanced bladder cancer.

Tumors shrank
(partial response)

46 out of 270 people, or 17%, saw tumors shrink in response to OPDIVO® for previously treated advanced bladder cancer.

Tumors shrank or disappeared completely (overall response)

53 out of 270 people, or 20%, saw tumors shrink or disappear completely in response to OPDIVO® for previously treated advanced bladder cancer.
Half of the people who responded to OPDIVO saw a response in two months. The shortest response lasted 2 months, and the longest response lasted 7 months.

Words to know

Overall response rate is the percentage of patients who responded to treatment. These patients saw their tumors either shrink or disappear completely.

Partial response is when a tumor reacts to treatment and shrinks.

Complete response is when a tumor reacts to treatment and disappears completely. This is the disappearance of any measurable tumors in response to treatment. This does not mean the cancer has been cured.

OPDIVO will not work for everyone. Individual results may vary.

Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

Nurse monitoring a gentleman's infusion of OPDIVO® (nivolumab) immunotherapy treatment.

Getting an infusion

See your recommended treatment plan and what to expect from an infusion

For adults with previously treated advanced bladder cancer (urothelial carcinoma)

OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the lining of the urinary tract (including the bladder, urethra, ureters, or renal pelvis [urothelial carcinoma]) when it has spread or grown (locally advanced or metastatic) and you have tried chemotherapy that contains platinum, and it did not work or is no longer working or your cancer worsened within 12 months of treatment with chemotherapy that contains platinum, either before or after surgery to remove your cancer.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.



1506-US-2400131   04/24